Obicetrapib and ezetimibe combination therapy lowers LDL cholesterol in high-risk patients
1. FDC obicetrapib plus ezetimibe significantly decreased LDL cholesterol levels by 48.6% compared to placebo. 2. Serious adverse events were ...
1. FDC obicetrapib plus ezetimibe significantly decreased LDL cholesterol levels by 48.6% compared to placebo. 2. Serious adverse events were ...
1. High-sensitivity C-reactive protein increased the risk of all-cause mortality by two- to three-fold among all three randomized trials. 2. ...
1. Among symptomatic patients with high low-density lipoprotein cholesterol levels considered high risk for atherosclerotic cardiovascular disease (ASCVD), absence of ...
1. In this study, improved sleep quality was associated with significantly decreased systolic blood pressure and increased high-density lipoprotein levels ...
1. In individuals aged 70-100 years, there was a significantly increased risk of myocardial infarction and atherosclerotic cardiovascular disease for ...
1. In patients aged ≥75 years, LDL cholesterol-lowering therapies reduced the risk for major vascular events, including cardiovascular death, myocardial ...
1. Evolocumab successfully reduced low density lipoprotein (LDL) cholesterol levels in pediatric patients with heterozygous familial hypercholesterolemia. 2. Non- high ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.